These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16778291)

  • 21. [Inhaled corticosteroid/beta-2 agonist therapy in moderate COPD].
    Yıldırım N
    Tuberk Toraks; 2010; 58(2):192-201. PubMed ID: 20865575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
    Breekveldt-Postma NS; Koerselman J; Erkens JA; Lammers JW; Herings RM
    Respir Med; 2007 Jul; 101(7):1398-405. PubMed ID: 17368011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple therapy vs. dual bronchodilator therapy for chronic obstructive pulmonary disease: Is it worth the cost?
    Horita N; Kaneko T
    Respir Investig; 2015 Jul; 53(4):173-5. PubMed ID: 26100178
    [No Abstract]   [Full Text] [Related]  

  • 24. Triple therapy for the management of COPD: a review.
    Gaebel K; McIvor RA; Xie F; Blackhouse G; Robertson D; Assasi N; Hernandez P; Goeree R
    COPD; 2011 Jun; 8(3):206-43. PubMed ID: 21513437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
    Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
    Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of bronchodilators in chronic obstructive pulmonary disease.
    Weder MM; Donohue JF
    Semin Respir Crit Care Med; 2005 Apr; 26(2):221-34. PubMed ID: 16088439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
    Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
    Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?
    López-Campos JL; Calero Acuña C
    Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):43-51. PubMed ID: 23551023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New drug therapy of chronic obstructive pulmonary disease].
    Kino H
    Nihon Rinsho; 2003 Dec; 61(12):2175-80. PubMed ID: 14674329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease.
    Oba Y
    Mayo Clin Proc; 2007 May; 82(5):575-82. PubMed ID: 17493425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity.
    Sin DD; Golmohammadi K; Jacobs P
    Am J Med; 2004 Mar; 116(5):325-31. PubMed ID: 14984818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trend of cost and utilization of COPD medication in Korea.
    Lee J; Lee JH; Kim JA; Rhee CK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():27-33. PubMed ID: 28031708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bronchodilators in chronic obstructive pulmonary disease (COPD)].
    Gillissen A; Buhl R; Rabe KF; Vogelmeier C; Welte T
    Med Klin (Munich); 2005 May; 100(5):246-54. PubMed ID: 15902378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies.
    Wise RA; Tashkin DP
    Am J Med; 2007 Aug; 120(8 Suppl 1):S4-13. PubMed ID: 17678942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined bronchodilator therapy in the management of chronic obstructive pulmonary disease.
    Friedman M
    Respirology; 1997; 2 Suppl 1():S19-23. PubMed ID: 9400691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP
    Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
    Cyr MC; Beauchesne MF; Lemière C; Aaron SD; Blais L
    Ann Pharmacother; 2010 Apr; 44(4):613-22. PubMed ID: 20233915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
    Price D; Gray A; Gale R; Asukai Y; Mungapen L; Lloyd A; Peters L; Neidhardt K; Gantner T
    Respir Med; 2011 Nov; 105(11):1635-47. PubMed ID: 21764277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.